STAT

NOVEMBER 13, 2023

has approved a preventive drug for post-menopausal women at risk of developing breast cancer wasn’t a shock to breast medical oncologist Abenaa Brewster. But the fact that a patient in her breast cancer prevention clinic hadn’t ever heard of such a possibility before was. The news that the U.K.

FDA 141

FDA 141

Pharmacy Times

APRIL 17, 2024

A clinical pharmacist details how treatment algorithms differ between early-stage and metastatic breast cancer.

81

81

STAT

OCTOBER 25, 2023

Participation in a clinical trial is often considered something of an equalizer in medicine. But a new study suggests that increasing trial diversity won’t be enough to eliminate health disparities. Read the rest…

141

141

Hospital Pharmacy Europe

JANUARY 24, 2024

The poly ADP-ribose polymerase (PARP) inhibitor talazoparib (brand name Talzenna) has been recommended by the National Institute for Health and Care Excellence (NICE) to treat a type of locally advanced or metastatic breast cancer. The trial did not show any difference in how long people live. So talazoparib is recommended.’

Chemotherapy 101

Chemotherapy Hospitals 101

European Pharmaceutical Review

JANUARY 19, 2024

The National Institute for Health and Care Excellence (NICE) has published final draft guidance recommending Pfizer’s TALZENNA ® (talazoparib) for HER2- negative, locally advanced or metastatic breast cancer with germline BRCA1 or BRCA2 mutations.

Chemotherapy 89

Chemotherapy Pharmaceutical Companies Pharmaceutical Companies Labelling 89

Pharmacy Times

APRIL 10, 2024

Focusing on metastatic breast cancer, Aimee Keegan, PharmD, BCOP, provides clinical insights on ensuring optimal adherence to CDK4/6 inhibitors.

65

65

European Pharmaceutical Review

JANUARY 5, 2024

This treatment has potential for hormone sensitive cancers such as breast cancer, and other oncology indications. First AI-generated small molecule drug enters Phase II trial Advancing an AI-designed breast cancer therapy Overexpression of KAT6A correlates with poor clinical outcomes in ER+/HER2- breast cancer.

109

109

STAT

MARCH 1, 2024

I recently started a patient with metastatic triple-positive breast cancer patient on a targeted therapy regimen consisting of capecitabine and neratinib, both oral chemotherapy pills that are dosed on a 21-day cycle. Read the rest…

Specialty Pharmacies 117

Specialty Pharmacies Chemotherapy 117

STAT

OCTOBER 17, 2023

Are 3D  mammograms  better than standard 2D imaging for catching advanced cancers? A clinical trial is recruiting thousands of volunteers — including a large number of Black women who face disparities in breast cancer death rates — to try to find out. Read the rest…

130

130

European Pharmaceutical Review

MARCH 22, 2024

Research suggests that combining ribociclib with hormone therapy improved invasive-free survival in stage 2 or 3 HR-positive, HER2-negative early breast cancer. And that is huge for this the group of patients, who make up 70 percent to 75 percent of breast cancer cases.”

82

82

Hospital Pharmacy Europe

JUNE 9, 2023

The combination of ribociclib and standard endocrine therapy improves invasive disease-free survival rates more than endocrine therapy alone in patients with early stage, hormone receptor–positive, HER2-negative (HR+/HER2-) breast cancer, according to recent data presented at ASCO 2023.

Dosage 98

Dosage Labelling Hospitals 98

Pharmacy Times

DECEMBER 14, 2023

Heather McArthur, MD, clinical director of breast oncology at UT Southwestern Medical Center, discusses the toxicities associated with antibody-drug conjugates (ADCs) used in breast cancer treatment at the 2023 San Antonio Breast Cancer Symposium.

65

65

Pharmaceutical Technology

FEBRUARY 8, 2024

DX-126262 is under clinical development by Hangzhou DAC Biotech and currently in Phase I for Breast Cancer.

98

98

European Pharmaceutical Review

JANUARY 3, 2024

Korserdu ® (elacestrant) is the first treatment indicated for ER+, HER2- advanced or metastatic breast cancer tumours with ESR1 mutations. Data supporting MHRA’s authorisation of Korserdu (elacestrant) Data from the Phase III EMERALD trial was published in the ASCO Journal of Clinical Oncology. months versus 1.9 months versus 1.9

105

105

Pharmaceutical Technology

APRIL 17, 2024

B-Vaxx is under clinical development by Imugene and currently in Phase II for Human Epidermal Growth Factor Receptor 2 Positive Breast Cancer (HER2+ Breast Cancer).

40

40

Pharmaceutical Technology

JANUARY 13, 2023

Health Canada has granted approval to Enhertu (trastuzumab deruxtecan) to treat unresectable or metastatic HER2-low (IHC 1+ or IHC 2+/ISH-) breast cancer. Enhertu’s safety profile was consistent with the previous clinical trials.

Adverse Reactions 128

Adverse Reactions Chemotherapy 128

STAT

SEPTEMBER 7, 2023

There’s a diversity problem in cancer clinical trials, and few know this better than Stephanie Walker. When she was diagnosed with stage 4 metastatic breast cancer, Walker said there was no one to help her figure out the system, not even a nurse or patient navigator.

128

128

European Pharmaceutical Review

JULY 24, 2023

A novel breast cancer treatment The anti-cancer therapeutic is indicated for postmenopausal women, and adult men, with these clinical biomarkers. The post Will ESR1-mutated breast cancer treatment gain approval? ESR1 mutations are acquired mutations that develop due to endocrine therapy exposure.

88

88

European Pharmaceutical Review

OCTOBER 26, 2023

In August 2023, Biswajit Podder, PhD, Oncology and Hematology Analyst at GlobalData shared that HER2-positive breast cancer “seems to be a major focus” in ADC drug development. Clinically meaningful PFS benefit was seen in patients with non-squamous tumours. Can you summarise the key new data from the TROPION-programme?

Chemotherapy 100

Chemotherapy 100

Pharmacy Times

JULY 8, 2022

Findings suggest that the HER2 L755S mutation plays a role in the aggressiveness of lobular breast cancer observed in the clinic.

139

139

pharmaphorum

OCTOBER 17, 2022

Bayer has added another clinical trial to its extensive phase 3 programme for oral neurokinin antagonist elinzanetant, hoping to show that it can treat vasomotor symptoms (VMS) in breast cancer patients. There are around 2.3

FDA 110

FDA 110

Pharmaceutical Technology

APRIL 19, 2024

SGN-1 is under clinical development by Guangzhou Huajin Pharmaceutical Technology and currently in Phase II for Breast Cancer.

40

40

Pharmacy Times

DECEMBER 8, 2023

Mara Hofherr, PharmD, a clinical oncology pharmacist at Washington University, highlights key findings of the KEYNOTE-522 trial in comparison of outcomes between Black and White patients with triple-negative breast cancer.

65

65

Pharmaceutical Technology

APRIL 17, 2024

SLATE-001 is under clinical development by Gritstone Bio and currently in Phase I for Metastatic Breast Cancer.

40

40

Dr. Jamie Hardy: The Lifestyle Pharmacist

OCTOBER 9, 2023

October is Breast Cancer Awareness Month. It’s a time dedicated to raising awareness about breast cancer, highlighting the importance of early detection, and supporting those affected by this disease. What is Breast Cancer? Breast cancer is a type of cancer that starts in the cells of the breast.

52

52

STAT

JANUARY 25, 2023

The dispute began when Eli Lilly challenged some of the information in an ad that Novartis had run for its Kisqali breast cancer treatment. Specifically, Lilly objected to language about the overall survival rate in Kisqali clinical trials that suggested the drug was superior to similar cancer medications.

FDA 97

FDA 97

Pharmaceutical Technology

FEBRUARY 19, 2024

AC-0682 is under clinical development by Accutar Biotechnology and currently in Phase I for Human Epidermal Growth Factor Receptor 2 Negative Breast Cancer (HER2- Breast Cancer).

40

40

pharmaphorum

FEBRUARY 21, 2022

Already making inroads as a treatment for HER2-positive breast cancer, AstraZeneca and Daiichi Sankyo’s Enhertu has now shown efficacy in tumours that express lower levels of HER2 – potentially making it an option for a much broader group of patients.

Chemotherapy 132

Chemotherapy Labelling 132

pharmaphorum

FEBRUARY 10, 2021

This is the primary industry platform specifically dedicated to providing you insight into the latest developments of safe and efficacious blockbuster therapies to treat triple negative breast cancer. The post Triple Negative Breast Cancer Drug Development Digital Summit appeared first on.

Immunization 133

Immunization Vaccines 133

Pharmaceutical Technology

AUGUST 8, 2022

AstraZeneca and Daiichi Sankyo ’s Enhertu (trastuzumab deruxtecan) has received expanded approval from the US Food and Drug Administration (FDA) to treat adults with unresectable or metastatic HER2-low (IHC 1+ or IHC 2+/ISH-) breast cancer. In these subjects, the median progression-free survival (PFS) following Enhertu treatment was 9.9

FDA 105

FDA Chemotherapy Labelling 105

Pharmaceutical Technology

FEBRUARY 7, 2024

Enfortumab vedotin is under clinical development by Astellas Pharma and currently in Phase II for Human Epidermal Growth Factor Receptor 2 Negative Breast Cancer (HER2- Breast Cancer).

40

40

Pharmaceutical Technology

FEBRUARY 7, 2024

Trastuzumab biosimilar is under clinical development by Qilu Pharmaceutical and currently in Phase III for Human Epidermal Growth Factor Receptor 2 Positive Breast Cancer (HER2+ Breast Cancer).

40

40

pharmaphorum

DECEMBER 12, 2022

The San Antonio Breast Cancer Symposium (SABCS) has highlighted some of the most promising clinical research being undertaken by drugmakers in the category, with AstraZeneca leading the charge with a trio of major trial readouts. after four years’ follow-up, an improvement on the 2.8% seen at two years.

Chemotherapy 104

Chemotherapy FDA 104

STAT

SEPTEMBER 8, 2022

Gilead Sciences said Wednesday that its cancer drug Trodelvy prolonged the survival of women with the most common form of breast cancer by just under 30% — a clinical trial result that could lead to a better treatment option for patients with advanced disease and strengthen the drug’s commercial outlook.

Chemotherapy 141

Chemotherapy 141

pharmaphorum

JULY 14, 2022

Cost-effectiveness watchdog NICE has recommended routine NHS use of two new therapies for women with advanced breast cancer – Gilead’s Trodelvy and Novartis’ Piqray – in England. .

Chemotherapy 104

Chemotherapy Pharmaceutical Companies Pharmaceutical Companies Labelling 104

European Pharmaceutical Review

JANUARY 26, 2023

Enhertu (trastuzumab deruxtecan) has been approved in the European Union (EU) for adults with unresectable or metastatic HER2-low (IHC 1+ or IHC 2+/ISH-) breast cancer. The antibody drug conjugate (ADC) is the first HER2-directed therapy for HER2-low metastatic breast cancer.

Chemotherapy 86

Chemotherapy 86

Pharmacy Times

DECEMBER 18, 2023

There is a prognostic impact of clinical and immunohistochemistry markers.

65

65